Navigation Links
Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
Date:2/25/2009

4 2009 (currently enrolling; conducted by Wyeth)

-- Announce SBI-087 Phase 1 rheumatoid arthritis trial data by end of Q4 2009 (currently enrolling; conducted by Wyeth)

-- Initiate SBI-087 Phase 1 systemic lupus erythematosus trial by end of Q1 2009 (conducted by Wyeth)

"Concentrating our resources on our clinical stage product candidates, as well as our preclinical programs that we believe have the greatest potential for value creation, while streamlining operations will increase our financial flexibility by reducing ongoing operating expenses and decreasing the need for additional financing in the short term," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "While this type of action is always very difficult, we believe these actions will provide us with the best opportunity for near-term success and establish a foundation for building long-term stockholder value. I would like to thank all Trubion employees for their ongoing dedication to our mission of becoming a leading provider of protein therapeutics for the treatment of autoimmune and inflammatory diseases and cancer."

Estimated charges of approximately $0.8 million will be recorded in the first quarter of 2009 in connection with one-time work-force reduction costs, including severance and other benefits. Trubion will continue to support the programs developed under its collaboration with Wyeth and all expenses incurred will continue to be reimbursed by Wyeth. Based on its current forecast, and excluding any proceeds from potential new partnerships or financings, the reductions announced today, in combination with targeted investments in preclinical and clinical programs, are expected to support the company's operations into the second half of 2010.

Trubion will announce financial results for the fourth quarter and year ended Dec. 31, 2008, on March 12, 2009, after market close.

'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Trubion Announces Presentations at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
3. Trubion Announces Presentations at Upcoming Investor Conferences
4. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
5. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
6. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Trubion Announces Presentations at April/May Investor Conferences
9. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
10. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ITRA Global, ... and occupiers of commercial real estate, has further expanded ... offices in Perth and Brisbane, Western Australia, reports Mylinda ... directors. , ITRA Global / ACORPP (Australian Corporate ... independent consultancy company providing property services to a wide ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), ... promotion of Nick Maroulis, Pharm.D. to the newly created ... , In this position, Dr. Maroulis will continue to ... directors of our multi-site pharmacies as the company expands. ... during that time he has served in many different ...
(Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... GE Healthcare will have the exclusive global distribution ... of a 15-year agreement with its developer, ThermoGenesis . ... the stem cell harvesting product, known as the Auto Express ... the world's largest chains of private umbilical cord blood banks. ...
... another turn last month when the District Court of New ... Inc ., v. GoTo.com, Inc . , ,Plaintiff JR ... Yahoo! , ,GoTo sold several keywords, including ... JR Cigar competitors. , ,As mentioned in my prior article ...
... nation's fifth largest school district is being outfitted with ... Inc. , to deter sexual predators from entering school ... to develop hybrid car batteries and energy-efficient building systems, ... utilizing digital identification checkpoints in 250 Broward County ...
Cached Biology Technology:Are consumers confused by search engine ads? 2Are consumers confused by search engine ads? 3Are consumers confused by search engine ads? 4Florida schools employ Johnson Controls technology to stop sex predators 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... key building block of life, actin is one of the ... First discovered in muscle cells more than 70 years ... that works by linking itself in chains to form filaments. ... contraction. So it came as a surprise when ...
... August 2011, researchers from the U.S. Department of Agriculture ... puzzle in Kennewick, Wash. Since Kennewick lies within a ... apple-growing region, an annual survey of fruit trees is ... to look for any invading insects. This time the ...
... boats, many invasive species are now covering our shorelines and ... a study published in Ecology Letters , Northeastern University ... some invasive species to survive in their new environments and ... Once invasive species arrive in their new location, ...
Cached Biology News:UT MD Anderson scientists uncover the nuclear life of actin 2UT MD Anderson scientists uncover the nuclear life of actin 3Genetic analysis saves major apple-producing region of Washington state 2Invasive species: Understanding the threat before it's too late 2
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
... Goat polyclonal to PAX3 This ... box (PAX) family of transcription factors. Members ... paired box domain and a paired-type homeodomain. ... development. Mutations in paired box gene 3 ...
Mouse monoclonal antibody to RNase L...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: